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The first human lung transplantation was per-
formed by James Hardy in Missouri 40 years ago
[1]. The recipient, who suffered from severe em-
physema and an obstructing carcinoma of the left
main stem bronchus, survived 18 days after a left
single lung transplant. Although Hardy’s pioneer
effort had failed, it demonstrated that human lung
transplantation was technically feasible. Until the
end of the seventies only 38 lung transplants were
performed world wide with dismal results [2–4].
Only one recipient could be discharged from the
hospital, but he died of pneumonia and chronic
rejection 10 months after transplantation [5]. In
1983, Cooper and his colleagues performed the
landmark single lung transplant procedure on a pa-
tient suffering from pulmonary fibrosis who was
the first long-term survivor [6]. It was the same
group who carried out the first successful sequen-
tial bilateral lung transplantation in 1989 [7]. This
procedure could also be performed in patients with
suppurateive lung disorders such as cystic fibrosis,
and it soon replaced heart-lung transplantation in
most centres. This latter technique now is mostly
used for patients with un-correctable cardiac mal-
formations and pulmonary hypertension.
Until today almost 15’000 lung transplant pro-
cedures have been reported in the Registry of the
International Society for Heart and Lung Trans-
plantation ISHLT [8, 9]. The most frequent indi-
cation was emphysema in 51% of the patients, fol-
lowed by parenchymal lung disorders in 21%, cys-
tic fibrosis in 19% and pulmonary hypertension in
6%. The current one, five and ten year survival
rates are 74%, 47% and 24% respectively. 
Objective: Lung transplantation has evolved
from an experimental procedure to a viable thera-
peutic option in many countries. In Switzerland,
the first lung transplant was performed in No-
vember 1992, more than ten years after the first
successful procedure world-wide. Thenceforward,
a prospective national lung transplant registry was
established, principally to enable quality control.
Patients: The data of all patients transplanted
in the two Swiss Lung Transplant centres Zurich
University Hospital and Centre de Romandie
(Geneva-Lausanne) were analysed. 
Results: In 10 years 242 lung transplants have
been performed. Underlying lung diseases were
cystic fibrosis including bronchiectasis (32%), em-
physema (32%), parenchymal disorders (19%),
pulmonary hypertension (11%) and lymphangio-
leiomyomatosis (3%). There were only 3% redo
procedures. The 1, 5 and 9 year survival rates were
77% (95% CI 72–82), 64% (95% CI 57–71) and
56% (95% CI 45–67), respectively. The 5 year sur-
vival rate of patients transplanted since 1998 was
72% (95% CI 64–80). Multivariate Cox regression
analysis revealed that survival was significantly bet-
ter in this group compared to those transplanted
before 1998 (HR 0.44, 0.26–0.75). Patients aged
60 years and older (HR 5.67, 95% CI 2.50–12.89)
and those with pulmonary hypertension (HR 2.01,
95% CI 1.10–3.65) had a significantly worse prog-
nosis The most frequent causes of death were in-
fections (29%), bronchiolitis obliterans syndrome
(25%) and multiple organ failure (14%). 
Conclusion: The 10-year Swiss experience of
lung transplantation compares favourably with 
the international data. The best results are ob-
tained in cystic fibrosis, pulmonary emphysema
and parenchymal disorders. 
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The first lung transplant in Switzerland was
performed November 10, 1992 at the Zurich Uni-
versity Hospital [10]. In February 15, 1993 the first
procedure was carried out by the Centre de Ro-
mandie. From the very beginning of the lung
transplantation era in Switzerland, the two centres
established a national registry on behalf of the
Swiss Transplant Working Group for Lung Trans-
plantation STALU to ascertain the necessary qual-
ity control data. Herein we report on our activities
during the past 10 years of experience.
Patients and methods
The data of all patients transplanted in the two Swiss
Lung Transplant centres Zurich University Hospital and
Centre de Romandie (Geneva-Lausanne) were prospec-
tively collected in a national registry. The following in-
formation was included: patients’ age, sex, underlying dis-
ease, date of transplantation, type of transplant, ie, single
or bilateral, ABO blood group and CMV serostatus of re-
cipient and donor, and date and cause of death.
The indications and contraindications were made ac-
cording to widely accepted criteria [11].
The operation was performed according to standard-
ised techniques and remained basically the same through-
out the whole study period [6, 7, 12, 13]. Cardiopulmonary
bypass was used mainly in primary or thromboembolic
pulmonary hypertension cases and only exceptionally in
other patients. All transplants were ABO-matched, and
none was HLA-matched. Recipients seronegative for cy-
tomegalovirus were given seronegative organs whenever
possible, but otherwise they received organs seropositive
for cytomegalovirus without restrictions throughout the
whole period.
The postoperative regimens at the two centres were
comparable with the exception of minor details which
have been described elsewhere [14–20] The induction
immunosuppressive regimen consisted of cyclosporine,
azathioprine, and a 5 to 10-day course of antithymocyte
globulins. In the Centre de Romandie and in Zurich bas-
iliximab has been used for induction immunosuppression
since 2000 and 2002, respectively.
Maintenance immunosuppressive drugs were cy-
closporine, azathioprine and tapered dose prednisone. In
Zurich, from 1999 onwards mycophenolate mofetil was
routinely used instead of azathioprine [20], whereas in the
Centre de Romandie it was used initially only for patients
with recurrent acute rejections or drug-induced chronic
renal failure [18]. In the Centre de Romandie, from 1998
on tacrolimus was used instead of cyclosporine in most pa-
tients [15]. 
Perioperative antibiotic prophylaxis consisted of a
second or third generation cephalosporin or an anti-
pseudomonas combination therapy tailored to the pre-
transplant bacteriological results in cystic fibrosis patients.
Postoperative antibiotic treatment was adapted according
to the detected bacterial strains. Pneumocystis carinii pro-
phylaxis was done with cotrimoxazole, three double
strength tablets per week. In patients with fungal coloni-
sation azoles or inhalative amphotericine was adminis-
tered [21, 22]. All patients at risk of CMV infections, ie,
transplant candidates having a positive CMV serology or
receiving the organ from a CMV-seropositive donor, re-
ceived prolonged prophylaxis with either intravenous or
oral ganciclovir for 5 to 9 months as described elsewhere
for CMV [14, 19]. After a cost benefit analysis it was re-
duced to 3 months in the Centre de Romandie [13]. Bac-
terial, fungal or protozoal infections were treated accord-
ing to standard criteria [23].
Patients were periodically followed up with evalua-
tions of lung function, fibreoptic bronchoscopy, and early
detection of antigens for CMV. Patients measured their
own FEV1 and FVC on a daily basis at home, and a de-
crease of 10% sustained for >2 days indicated the need for
further investigation. Complete lung function evaluations
were performed regularly in the pulmonary function lab-
oratory. Regular bronchoscopy procedures were per-
formed as part of the postoperative surveillance during the
first 6 to 12 months as described elsewhere [17, 24]. Re-
jection and infection were evaluated through trans-
bronchial lung biopsies, BAL cellularity, transbronchial
biopsies, Gram stain, and bacterial and viral cultures.
Acute rejection episodes were treated with methylpred-
nisolone pulses. Antilymphocyte globulins were given in
patients with recurrent acute rejection episodes.
Results are expressed as median and ranges, or as
mean with 95% confidence intervals (95% CI) if appro-
priate. Standard life-table analysis and the Kaplan-Meier
statistics were used to estimate overall survival distribu-
tion. 95% CI’s were calculated from the Greenwood’s
standard errors (see Kalbfleisch and Prentice, 2002: The
Statistical Analysis of Failure Time Data. 2nd Edition. New
York; John Wiley & Sons). Potential predictors of survival
were assessed with the Cox proportional hazards analysis.
We included age, sex, centre, type of lung disease, trans-
plant procedure, ie. single versus bilateral, CMV serosta-
tus and era (until 1997 v. period since 1998) in the model,
and excluded in a backward stepwise procedure the vari-
ables with a p >0.1. In order to obviate correlated obser-
vations, retransplantations were excluded from this analy-
sis. Data are expressed as hazard ratios (HR). A p value
<0.05 was considered to be significant. 
Results
Between November 1992 and November 2002
a total of 242 lung transplants have been per-
formed. There were 110 female and 132 male pa-
tients with a median age of 45 years (range 7 to 66
years). The age and sex distribution is shown in fig-
ure 1. Twelve of the patients (5%) were children
aged below 16 years. Zurich University Hospital
performed 131 and the Centre de Romandie 111
transplant procedures. The annual transplantation
rates at the two centres are shown in figure 2.
The most frequent underlying lung diseases
(figure 3) were cystic fibrosis (n = 77) including 
7 cases with non-CF bronchiectasis, emphysema
(n = 78) including 23 patients with alpha-1-anti-
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The specific diagnoses in the parenchymal dis-
orders group were: idiopathic pulmonary fibrosis
(n = 34), sarcoidosis (n = 5), Langerhans cell his-
tiocytosis (n = 4), and one case each of acute res-
piratory distress syndrome, pulmonary fibrosis due
to systemic sclerosis, giant cell interstitial pneu-
monia in a hard metal worker, and idiopathic pneu-
monia syndrome after bone marrow transplan-
tation. The specific diagnoses in the pulmonary
hypertension group were: idiopathic pulmonary
arterial hypertension (n = 15), chronic thrombo-
embolic pulmonary hypertension (n = 7), and one
case each of pulmonary arterial hypertension relat-
ed to systemic sclerosis, pulmonary arterial hyper-
tension with significant veno-occlusive involve-
ment, peripheral pulmonary artery stenosis, and
Eisenmenger syndrome. 
The one, three, five and nine-year survival
rates were 77%, 67%, 64% and 56%, respectively,
which compares favourably with the results of 
the registry of the International Society of Heart
and Lung Transplantation ISHLT (figure 4). The
5-year survival rate of patients transplanted in
Switzerland since 1998 was 72% (95% CI 64–80)
compared with 57% (95% CI 48–66) in those re-
ceiving a transplant before that time point. Al-
though a direct statistical comparison was not
done, it becomes evident from the comparison of
the 95% confidence intervals of the survival data
from the Swiss and the ISHLT registry, respec-
tively, that the Swiss figures significantly surpass
those of the ISHLT from the third postoperative
year on (table 1).
Eighty patients died after a median of 152 days
(1 to 3310 days) after transplantation. The most
frequent causes of death (table 2) were infections
in 23 patients (29%) caused by bacteria (n = 13),
viruses (n = 4), fungi (n = 5) and 1 M. tuberculosis
(n = 1), followed by bronchiolitis obliterans syn-
drome in 20 instances (25%) and multiple organ
failure in 9 patients (14%). Less frequent causes of
death were neoplasia (3 post-transplant lympho-
Figure 1
Age and sex distribu-
tion of the patients
transplanted in
Switzerland between
November 1992 and
November 2002 
(n = 242).
Figure 2
Annual transplanta-
tion rates in the two
centres (ZH = Zurich
University Hospital;
RO = Centre de
Romandie).
Year post- Swiss Registry ISHLT Registry
transplant (n = 242) (n = 14’489)
1 77 (72–82) 74 (73–74)
2 71 (66–77) 65 (65–66)
3 67 (60–73) 58 (57–59)
4 65 (59–72) 52 (51–53)
5 64 (57–71) 47 (46–48)
6 63 (56–70) 41 (40–42)
7 63 (56–70) 37 (35–38)
8 60 (52–69) 32 (31–33)
9 56 (45–67) 28 (27–30)
* Survival rates are given as mean and 95% confidence intervals. 
The figures from the ISHLT Registry are kindly provided by
Leah Bennett Edwards, Ph.D., ISHLT Registry, Associate
Director for Data Analysis, and UNOS, Assistant Director 
of Research, Richmond, USA 
Table 1
Survival rates of the
Swiss cohort com-
pared to the data of
the ISHLT Registry*.
trypsin deficiency and 2 with non-transplant oblit-
erative bronchiolitis, followed by parenchymal dis-
orders (n = 47), pulmonary hypertension (n = 26)
and lymphangioleiomyomatosis (n = 6). There
were only 8 retransplantations. Both lungs were
transplanted in 188 and single lungs in 54 patients. 
S W I S S  M E D  W K LY 2 0 0 4 ; 1 3 4 : 1 8 – 2 3 ·  w w w. s m w. c h 21
after central venous catheter misplacement (1), and
after transbronchial lung biopsy (1).
The most frequent causes of death (table 2)
within the first postoperative month were multiple
organ failure (35%), infections (27%), central
nervous system disorders (15%) and cardiac fail-
ure (12%). The most frequent causes of death be-
tween postoperative month two and twelve were
infections (40%) and bronchiolitis obliterans syn-
drome (18%). The most frequent causes of death
after the first postoperative year were bronchio-
litis obliterans syndrome (54%), neoplasia (21%),
and infections (17%). 
The multivariate Cox regression analysis re-
vealed that there was no difference in survival be-
tween the two centres. Neither sex, type of trans-
plant (single v. bilateral) nor the donor/recipient
serostatus for cytomegalovirus influenced the sur-
vival rate. However, patients aged 60 years and
older (HR 5.67, 95% CI 2.50–12.89) and those
with pulmonary hypertension (HR 2.01, 95% CI
1.10–3.65) had a significantly worse prognosis. On
the other hand, patients transplanted since 1998
had a significantly improved survival (HR 0.44,
0.26–0.75).
Figure 4
Kaplan-Meyer esti-
mates of overall sur-
vival after lung trans-
plantation in Switzer-
land compared to the
data of the Registry
of the International
Society for Heart and
Lung Transplantation
(ISHLT). The patients
transplanted in
Switzerland since
1998 had a signifi-
cantly improved
prognosis (hazard
ratio 0.44; p = 0.002).
Figure 3
Distribution of the
main diagnostic
groups.
Cause of death first month month 2 to 12 year 2 and later overall
(n = 26) (n = 30) (n = 24)
Infection 7 12 4 23
Bronchiolitis obliterans syndrome 7 13 20
Multiple organ failure 9 2 11
Neoplasia 1 5 6
Gastrointestinal complications 1 3 1 5
Central nervous system disorders 4 1 5
Graft-related technical problems 2 3 5
Cardiac failure 3 3
Accidents 1 1 2
Table 2
Causes of death in 
80 lung transplant
recipients.
proliferative disorders, 3 carcinomas), gastroin-
testinal complications (3 perforated diverticu-
litis, 2 mesenteric infarctions), central nervous
system disorders (2 idiopathic hyper-ammonaemia,
2 hypoxic-ischaemic encephalopathy, 1 cerebral
oedema due to superior vena cava thrombosis),
cardiac failure, and accidents. Only 5 patients (2%
of all transplant recipients) died as a direct or in-
direct consequence of technical problems: pul-
monary artery rupture (1) and thrombosis (1),
haemorrhage after stenting of airway stenosis (1),
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The results of our 10-years’ experience
demonstrate that in Switzerland lung transplanta-
tion has been established as a viable therapeutic
option in the management of end-stage diseases of
the lungs and the pulmonary circulation. Our sur-
vival rates are clearly superior to those reported in
the international registry, and they have even im-
proved during the recent years. The reasons for
this success are many-fold, but among the first is
the fact that in both centres a constant, dedicated
and highly motivated team with close relationships
to the international transplant community has
been responsible for the two programmes. The
constancy of an experienced team is of utmost im-
portance for the careful selection of patients, the
competent surgical techniques, the sophisticated
perioperative management, meticulous surveil-
lance and complex long-term management. 
Careful selection of patients is the backbone of
successful lung transplantation [25, 26]. Only one
third of the patients suffer from relatively common
diseases such as pulmonary emphysema [27]. An-
other third consists of patients with cystic fibrosis,
which is quite uncommon in relation to the gen-
eral population, but for which the indication crite-
ria are well established [11]. The remainder of
cases consists of very rare lung disorders such as
pulmonary fibrosis [28], sarcoidosis, Langerhans’
cell granulomatosis, lymphangioleiomyomatosis
[29], obliterative bronchiolitis and disorders of the
pulmonary circulation [30]. Especially in the latter
group of patients, the complex and highly spe-
cialised management of the disease itself goes
along with the evaluation for a lung transplanta-
tion and depends on an experienced team of spe-
cialists for orphan’s lung disease. The importance
of careful selection of potential lung transplant
candidates is underscored by our data, which
demonstrate a significantly worse survival in pa-
tients aged 60 or higher and in those with pul-
monary hypertension.
Surgical expertise is the sine qua non condition
for successful lung transplantation. It is quite re-
markable that only five of our patients (2%) died
because of technical problems, and in only three of
them the cause of death was directly or indirectly
related to surgery. Whereas other lung transplant
programmes still suffer from a significant propor-
tion of patients with bronchial anastomotic com-
plications, only one patient in our series died be-
cause of haemorrhage after stenting of a bronchial
anastomotic stenosis. 
The perioperative management of the lung
transplant recipient is highly demanding. About
10% of our patients died during this period, mul-
tiple organ failure being the most frequent cause
followed by cardiac failure. In most of these pa-
tients the exact reason for the organ failure could
not be determined. Early allograft dysfunction due
to re-perfusion injury, acute rejection or occult
infections may have played a role. There is clearly
need for improvement in this period. However,
even in the retrospective analysis of these cases, it
is difficult to determine, how this could have been
accomplished. 
The intermediate and long-term management
of these patients is determined by the most fre-
quent complications, ie, infections and bronchio-
litis obliterans syndrome. Meticulous postoperative
surveillance, prophylactic measures and pre-emp-
tive antimicrobial treatment of infections are cru-
cial [22, 23, 31]. It is striking, that after bronchi-
olitis obliterans syndrome bacterial infections
were the most frequent specific cause of death.
Therefore, in the future, emphasis on early diag-
nosis and aggressive treatment even only on suspi-
cion of this complication, is a primary goal. 
The fact that only a few patients were lost to
viral or fungal infections reflects our policies of
long-term ganciclovir prophylaxis [14, 19] and
pre-emptive antifungal strategies [21, 22]. The
benefit of cytomegalovirus prophylaxis is also
underscored by the fact that neither cyto-
megalovirus-seropositive lung transplant recip-
ients nor seronegative recipients of seropositive
organs had an impaired prognosis.
Bronchiolitis obliterans syndrome (BOS) still
presents the most important single cause of death
after lung transplantation [32]. It is believed to be
caused by various immunological and non-im-
munological injuries to the pulmonary allograft
with a common final pathway often presenting as
progressive airflow obstruction with histological
features of obliterative bronchiolitis. The most
frequently discussed risk factors are infections,
such as with cytomegalovirus, chronic aspiration
and recurrent acute rejection [33]. The number
and the severity of acute rejection episodes are the
most clearly defined risk factors. Many acute re-
jection episodes occur during the first months after
lung transplantation and are often asymptomatic.
Therefore, regular surveillance transbronchial
lung biopsies [24], which are carried out in both
centres, are crucial for picking-up and treating
these acute rejection episodes early and thereby
possibly reducing the incidence of BOS. More-
over, it may also be important to recognise late
acute rejection episodes early, in particular the mo-
ment the lung function decreases or does not re-
cover after an inter-current pulmonary infection.
These infections, irrespective of type, are well
known as triggers of innate and then specific cel-
lular immunity [34]. 
So far, as published elsewhere [20], the poten-
tial benefit of our policy of a strict and compre-
hensive surveillance after lung transplantation may
be underscored by the low risk of BOS of about 
22–25% after three to five years compared to the
figures reported in literature that are constantly
higher than 50%. 
Discussion
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Although it is well known from the interna-
tional registry data [8], that centres performing
only 10 or 5 lung transplants per year have a higher
mortality at 14% and 21%, respectively, we feel
that our excellent results in comparison to the
benchmark data and despite a maximum annual
case load of about 30 transplants in Switzerland,
which leads to a annual transplantation rate of
about 15 per centre, justify the maintenance of two
lung transplant centres in our country.
In conclusion, lung transplantation has be-
come a viable therapeutic option for severely dis-
abled patients with the best results being obtained
in cystic fibrosis, pulmonary emphysema and fi-
brosis. The 10-year Swiss experience compares
very favourably with the international benchmark
data. Strategies to prevent bronchiolitis obliterans,
probably representing sequelae of early or late
acute rejection episodes, infections, and non-im-
mune injuries to the lung allograft, are crucial.
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